Ge Long Hui·2025-10-24 09:49Core Viewpoint - China Resources Pharmaceutical (03320.HK) reported a decline in total revenue for Jiangzhong Pharmaceutical, with a total revenue of RMB 2.933 billion for the nine months ending September 30, 2025, representing a year-on-year decrease of 6.28% [1] - The net profit for the same period was RMB 743 million, showing a year-on-year increase of 6.02% [1] - The cash and cash equivalents at the end of the period amounted to RMB 767 million [1] Financial Performance - Total revenue for Jiangzhong Pharmaceutical: RMB 2.933 billion, down 6.28% year-on-year [1] - Net profit: RMB 743 million, up 6.02% year-on-year [1] - Cash and cash equivalents: RMB 767 million at the end of the reporting period [1] Ownership Structure - China Resources Pharmaceutical holds approximately 43.14% equity in its non-wholly owned subsidiary, China Resources Jiangzhong Pharmaceutical Group Co., Ltd. [1] - The company has actual control over Jiangzhong Pharmaceutical at 26.12%, accounted for as a subsidiary [1]